Selective sensitization of adriamycin-resistant P388 murine leukemia cells to antineoplastic agents following transfection with human DNA topoisomerase IIα

Anticancer Research

Volumn 17, Issue 6 D, 1997, Pages 4243-4252

  McPherson, J Peter ^a   Deffie, Abdul M ^a   Jones, Nik R ^a   Brown, Greg A ^a   Deuchars, Kathryn L ^a   Goldenberg, Gerald J ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Adriamycin; DNA topoisomerase II; Multifactorial resistance; Transfection

Indexed keywords

ANTINEOPLASTIC AGENT; COMPLEMENTARY DNA; DACTINOMYCIN; DAUNORUBICIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; ETOPOSIDE; HYGROMYCIN B; MESSENGER RNA; METALLOTHIONEIN; MITOXANTRONE; VINCRISTINE;

ALLELE; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG SENSITIVITY; EXPRESSION VECTOR; GENE CONSTRUCT; GENE EXPRESSION; GENE REARRANGEMENT; GENETIC COMPLEMENTATION; GENETIC TRANSFECTION; LEUKEMIA P 388; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL SURVIVAL; DNA TOPOISOMERASES, TYPE II; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; GENETIC VECTORS; HUMANS; LEUKEMIA P388; MICE; RECEPTORS, RETINOIC ACID; RECOMBINANT FUSION PROTEINS; TRANSFECTION; TUMOR CELLS, CULTURED; TUMOR STEM CELL ASSAY;

EID: 0031418806     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Deffie AM, Alam T, Seneviratne C, Beenken SW, Batra JK, Shea TC, Henner WD and Goldenberg GJ: Multifactorial resistance to Adriamycin: relationship of DNA repair, glutathione transferase activity, drug efflux, and P-glycoprotein in cloned cell lines of Adriamycin-sensitive and -resistant P388 leukemia. Cancer Res 48: 3595-3602, 1988.
2. Ziljlstra JC, de Vries EGE and Mulder NH: Multifactorial drug resistance in an adriamycin-resistant human small cell lung carcinoma cell line. Cancer Res 47: 1780-1784, 1987.
3. Friche E, Danks MK, Schmidt CA and Beck WT: Decreased DNA topoisomerase II in Daunorubicin-resistant Ehrlich ascites tumor cells. Cancer Res 51: 4213-4218, 1991.
4. Cole SPC, Chanda ER, Dicke FP, Gerlach JH and Mirski SEL: Non-P-glycoprotein-mediated multidrug resistance in a small cell lung cancer cell line: evidence for decreased susceptibility to drug-induced DNA damage and reduced levels of topoisomerase II. Cancer Res 57; 3345-3352, 1991.
5. Deffie AM, Batra JK and Goldenberg GJ, Direct correlation between DNA topoisomerase II activity and cytotoxicity in Adriamycin-sensitive and -resistant P388 leukemia cell lines. Cancer Res 49: 58-62, 1989.
6. Goldenberg GJ, Wang H and Blair GW: Resistance to Adriamycin: relationship of cytotoxicity to drug uptake and DNA single-and double-strand breakage in cloned cell lines of Adriamycin-sensitive and -resistant P388 leukemia. Cancer Res 46: 2978-2983, 1986.
7. Deffie AM, McPherson JP, Gupta RS, Hedley DW and Goldenberg, GJ: Multifactorial resistance to antineoplastic agents in drug-resistant P388 murine leukemia, Chinese hamster ovary, and human HeLa cells, with emphasis on the role of DNA topoisomerase II. Biochem. Cell Biol 70: 354-364, 1992.
8. Deffie AM, Bosman DJ and Goldenberg GJ: Evidence for a mutant allele of the gene for DNA topoisomerase II in Adriamycin-resistant P388 murine leukemia cells. Cancer Res 49: 6879-6882, 1989.
9. McPherson JP, Brown GA and Goldenberg GJ: Characterization of a DNA Topoisomerase II α gene rearrangement in Adriamycin-resistant P388 leukemia: expression of a fusion messenger RNA transcript encoding Topoisomerase II α and the retinoic acid receptor α locus. Cancer Res 53: 5885-5889, 1993.
10. Leroy P, Krust A, Zelent A, Mendelsohn C, Garnier J-M, Kastner P, Dierich A and Chambon P: Multiple isoforms of the mouse retinoic acid receptor α are generated by alternative splicing and differential induction by retinoic acid. EMBO J 10: 59-69, 1991.
11. Sambrook J, Fitsch EF and Maniatis T: Molecular Cloning: A Labroratory Manual. Cold Spring Harbour Laboratory, Cold Spring Harbour, (1989).
12. Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB: Evaluation of a Tetrazolium-based Semiautomated Colorimetric Assay: Assessment of Chemosensitivity Testing. Cancer Res 47: 936-942, 1987.
13. Brown GA, McPherson JP, Gu L, Hedley DW, Toso R, Deuchars KL, Freedman MH and Goldenberg GJ: Relationship of DNA Topoisomerase II α and β expression to cytotoxicity of anti-neoplastic agents in human Acute Lymphoblastic Leukemia cell lines. Cancer Res 55: 78-82, 1995.
14. 3H-cystosine arabinoside and its effect on murine leukemic cells (L5178Y). Biochem Pharmacol 17: 753-767, 1968.
15. Adachi N, Miyaike M, Ikeda H and Kikuchi A: Characterization of cDNA encoding the mouse DNA topoisomerase II that can complement the budding yeast top2 mutation. Nucleic Acids Res 20: 5297-5303, 1992.
16. Hochhauser D and Harris AL: The role of topoisomerase II α and β in drug resistance. Cancer Treat Rev 19: 181-194, 1993.
17. Vassetzky YS, Aghisi G-C and Gasser SM: DNA topoisomerase II mutations and resistance to anti-tumor drugs. Bioessays 17: 767-774, 1995.
18. Chan VTW, Ng S, Eder JP and Schnipper LE: Molecular cloning and identification of a point mutation in the topoisomerase II cDNA from an etoposide-resistant Chinese Hamster Ovary cell line. J Biol Chem 268: 2160-2165, 1993.
19. Tan KB, Mattern MR, Eng W-K, McCabe FL and Johnson RK: Nonproductive rearrangement of DNA topoisomerase I and II genes: correlation with resistance to topoisomerase inhibitors. J. Natl Cancer Inst 81: 1732-1735, 1989.
20. Binaschi M, Giaccone G, Gazdar AF, De Isabella P, Astaldi Ricotti GCB, Capranico, G and Zunino F: Characterization of a topoisomerase II gene rearrangement in a human small-cell lung cancer cell line. J Natl Cancer Inst 84: 1710-1716, 1992.
21. Harker WG, Slade DL, Parr RL, Feldhoff PW, Sullivan DM and Hoguin MH: Alterations in the topoisomerase IIα gene, messenger RNA, and subcellular protein distribution as well as reduced expression of the DNA topoisomerase IIα enzyme in a Mitoxantrone-resistant HL-60 human leukemia cell line. Cancer Res 55: 1707-1716, 1995.
22. Mirski SE and Cole SPC: Cytoplasmic localization of a mutant Mr 160,000 topoisomerase IIα is associated with the loss of putative bipartite nuclear localization signals in a drug-resistant human lung cancer cell line. Cancer Res 55: 2129-2134, 1995.
23. Squire J, McPherson JP, Beatty BG and Goldenberg GJ: Allelic fusion of DNA topoisomerase IIα and retinoic acid receptor a genes in Adriamycin-resistant P388 murine leukemia revealed by fluorescence in situ hybridization. Cytogenet Cell Genet 75: 164-166, 1996.
24. Nitiss JL, Liu Y-X, Harbury P, Jannatipour M, Wasserman R and Wang JC: Amsacrine and etoposide hypersensitivity of yeast cells overexpressing DNA topoisomerase II. Cancer Res 52: 4467-4472, 1992.
25. Wasserman RA, Austin CA, Fisher LM and Wang JC: Use of yeast in the study of anticancer drugs targeting DNA topoisomerases: expression of a functional recombinant human DNA topoisomerase IIα in yeast. Cancer Res 53: 3591-3596, 1993.
26. Worland ST and Wang JC: Inducible overexpression, purification, and active site mapping of DNA topoisomerase II from the yeast Saccharomyces cereivisiae. J Biol Chem 264: 4412-4416, 1989.
27. Bae Y-S, Kawasaki I, Ikeda H and Liu LF: Illegitimate recombination mediated by calf thymus DNA topoisomerase II in vitro. Proc Natl Acad Sci USA 85: 2076-2080, 1988.
28. Gudkov AV, Zelnick CR, Kazarov AR, Thimmapaya R, Suttle DP, Beck WT and Roninson IB: Isolation of genetic suppressor elements, inducing resistance to topoisomerase II-interacting cytotoxic drugs, from human topoisomerase II cDNA. Proc Natl Acad Sci USA 90: 3231-3235, 1993.
29. Eder JP, Chan VT-W, Niermierko E, Teicher BA and Schnipper LE: Conditional expression of wild-type topoisomerase II complements a mutant enzyme in mammalian cells. J Biol Chem 268: 13844-13849, 1993.
30. Resnitzky D, Gossen M, Bujard H and Reed SI: Acceleration of the G1/S phase transition by expression of cyclins D1 and E with an inducible system. Mol Cell Biol 14: 1669-1676, 1994.
31. Kuerbitz SJ, Plunkett BS, Walsh WV and Kastan MB: Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA 89: 7491-7495, 1992.
32. Chen P-L, Chen Y, Bookstein R and Lee W-H: Genetic mechanisms of tumor suppression by the human p53 gene. Science 250: 1576-1580, 1990.
33. Baker SJ, Markowitz S, Fearon ER, Willson JKV and Vogelstein B: Suppression of Human Colorectal Carcinoma cell growth by wild-type p53. Science 249: 912-915, 1990.
34. Tsai-Pflugfelder M, Liu LF, Liu AA, Tewey KM, Whang-Peng J, Knutsen T, Huebner K, Croce CM and Wang JC: Cloning and sequencing of cDNA encoding human DNA topoisomerase II and localization of the gene to chromosome region 17q21-22. Proc Natl Acad Sci USA 85: 7177-7181, 1988.
35. Karin M and Richards RI: Human metallothionein genes - primary structure of the metallothionein II gene and related processed gene. Nature 299: 797-799, 1982.
36. Oesterreich S, Wend C-N, Qiu M, Hilsenbeck SG, Osborne CK and Fuqua SAW: The small heat shock protein hsp27 is correlated with cell growth and drug resistance in human breast cancer cell lines. Cancer Res 53: 4443-4448, 1993.
37. Wasserman K, Markovits J, Jaxel C, Capranico G, Kohn KW and Pommier Y: Effects of Morpholinyl Doxorubicins, Doxorubicin and Actinomycin D on Mammalian Topoisomerases I and II. Mol Pharmacol 38: 38-45, 1990.
38. Inaba M and Sakuri Y: Enhanced efflux of actinomycin D, vincristine and vinblastine in Adriamycin-resistant sublines of P388 leukemia. Cancer Lett 8: 111-115, 1979.